All the CNS PM-AI- BIO based Knowledge verification done in the labs work by AVXL to this point must next be converted to H/W-S/W and other medical science concepts for the conversion of theory into products that do new work.
“I am excited to welcome Ms. Ma to Anavex’s Board of Directors,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Ms. Ma brings extensive experience in innovative product launches to Anavex. I am confident she will make important contributions to our Board of Directors and towards the commercial development of ANAVEX®2-73.”
As shareholders we are often decoupled from what the real AVXL plans are, IMO. He might try to tell us but we would not get it b/c we look at sp and trials as the metric that matters. If we assume the trials and such events are in the bag then the "SO WHAT??" issues are what leadership does. IMO, that kind of insight does not intuitively convert in WS value. Unless we trust the process. That is what just happened, IMO.
Ms. MA's placement is an example of such leadership. Why would a tiny bio-clinical company place leader in H/W-S/W-physics on the staff? IMO, That's why and also splains a little of why this is such a tricky investment. IMO, now that the BIO-science is in the bag, we prepare for the SO WHAT stuff.
AI
Market Data 
Markets 
